期刊文献+

单纯侵犯腹膜的T4期肾癌临床分析 被引量:1

Clinical features and prognosis of renal cell carcinoma patients with peritoneal invasion only
原文传递
导出
摘要 目的 了解单纯侵犯腹膜并且无淋巴结及全身转移的T4期肾癌患者的临床特点及手术疗效.方法 回顾性分析1999年1月至2012年2月收治的16例单纯侵犯腹膜并且无淋巴结及全身转移的T4期肾癌患者的临床资料,男9例,女7例.年龄33~ 78岁,中位年龄65岁.肿瘤位于左肾6例,右肾10例.肾肿瘤最大径5.5~ 17.0 cm,中位数为8.5 cm.16例均侵犯腹膜.16例均成功行根治性肾切除术及受累腹膜切除术.术后病理诊断透明细胞癌14例,乳头状肾细胞癌2例.结果 单纯侵犯腹膜的T4期肾癌占同期收治肾癌的0.21%(16/2 889),占同期T4期肾癌的21.62%(16/74).16例均获随访,随访时间18~134个月,其中8例术后出现远处转移,中位转移时间6.5个月;术后无瘤生存9例(其中1例甲状腺转移行手术切除后无瘤生存),带瘤生存1例,死亡6例.3年、5年累积生存率分别为79.32%和64.90%.结论 单纯侵犯腹膜的T4期肾癌临床上少见,通过手术完整切除患肾及受侵犯的腹膜者预后良好. Objective To study the clinical features and prognosis of renal cell carcinoma patients with peritoneal invasion but without lymphatic or systemic metastasis (T4NoM0). Methods We reviewed patients with pathological stage of T4NoM0 from Jan. 1999 to Feb. 2012. There were 16 patients (9 males, 7 females) met the inclusion criteria. There were 6 tumors on the left while other 10 on right. The median pa- tient age was 65 (ranged from 33-78) years, the medium size of the mass was 8.5 (ranged from 5.5-17.0) cm. Peritoneum was invaded in all these patients and all of them had radical nephrectomy and resection of a contiguous peritoneum successfully. Results These patients accounted for 0.21% (16/2889) of all renal cell carcinoma cases or 21.62% (16/74) of all T4NxM cases during this period. All patients were followed- up for 18-134 month. Metastases were found in 8 patients at a median 6.5 (ranged from 1-41) month after surgery. 9 patients were survival with disease-free, 1 patient were survival with disease progression, 6 pa- tients died after surgery. The 3 years and 5 years of cumulative survival rate were 79.32% and 64.90%, re- spectively. Conclusions The incidence of renal cell carcinomas with peritoneal invaded only is rare. Pa- tients accept a successfully radical nephrectomy and resection of a contiguous peritoneum will have a good prognosis.
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2014年第3期165-167,共3页 Chinese Journal of Urology
关键词 肾癌 外科治疗 预后 Renal cell carcinoma Surgery Prognosis
  • 相关文献

参考文献15

  • 1Park JW,Jo MK,Lee HM.Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma[J].BJU Int,2009,103:615-619.
  • 2Nativ O,Sabo E,Reiss A,et al.Clinical significance of tumor angiogenesis in patients with localized renal cell carcinoma[J].Urology,1998,51:693-696.
  • 3Bechtold RE,Dyer RB,Zagoria R J,et al.The perirenal space:relationship of pathologic processes to normal retroperitoneal anatomy[J].Radiographics,1996,16:841-854.
  • 4Karellas ME,Jang TL,Kagiwada MA,et al.Advanced-stage renal cell carcinoma treated by radical nephrectomy and adjacent organ or structure resection[J].BJU Int,2009,13:160-164.
  • 5Margulis V,Sanchez-Ortiz RF,Tamboli P,et al.Renal cell carcinoma clinically involving adjacent organs:experience with aggressive surgical management[J].Cancer,2007,109:2025-2030.
  • 6Guethmundsson E,Hellborg H,Lundstam S,et al.Metastatic potential in renal cell carcinomas </=7 cm:Swedish Kidney Cancer Quality Register data[J].Eur Urol,2011,60:975-982.
  • 7Abel EJ,Culp SH,Meissner M,et al.Identifying the risk of disease progression after surgery for localized renal cell carcinoma[J].BJU Int,2010,106:1277-1283.
  • 8Ares VY.Correlation between symptoms and survival in patients with renal cell carcinoma[J].Arch Esp Urol,2009,62:201-206.
  • 9Skinner DG,Colvin RB,Vermillion CD,et al.Diagnosis and management of renal cell carcinoma.a clinical and pathologic study of 309 cases[J].Cancer,1971,28:1165-1177.
  • 10Flanigan RC,Mickisch G,Sylvester R,et al.Cytoreductive nephrectomy in patients with metastatic renal cancer:a combined analysis[J].J Urol,2004,171:1071-1076.

二级参考文献13

  • 1Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev, 2005, 25 : 1425.
  • 2Motzer RJ, Baeik J, Murphy BA, et al. Interferonalfa as a comparative treatment for clinical trials of new therapiesagainst advanced renal cell carcinoma. J Clin Oncol, 2002, 20: 289-296.
  • 3Negrier S, Perol D, Ravaud A, et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. J Clin Oncol, 2005, 23 (Suppl) : 380.
  • 4Flanigan RC, Blumenstein BA, Salmon SE. Cytoreduction nephrectomy in metastatic renal cancer: the results of Southwest Oncology Group Trial 8949. J Clin Oncol, 2000, 18(Suppl): 3.
  • 5Mickisch GHJ, Garin A, van Poopel H, et al. Radical nephrectomy plus interferon alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma., a randomized trial. Lancet, 2001, 358: 966-970.
  • 6Bromwich E, McMillan DC, Lamb GW, et al. The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br J Cancer, 2004, 91 : 1236-1238.
  • 7Bracarda S, Porta C, Boni C, et al. Randomized prospective phase Ⅱ trial of two schedules of sorafenib daily and interfer-on-α2a (IFN) in metastatic renal cell carcinoma (RAPSODY) : GOIRC Study 0681. J Clin Oncol, 2007, 25(Suppl) : 259.
  • 8Escudier B, Koralewski P, Pluzanska A, et al. A randomized, controlled, double-blind phase Ⅲ study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol, 2007, 25(Suppl) : 2.
  • 9Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007, 356 : 125-134.
  • 10Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebocontrolled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006, 24: 2505-2512.

共引文献12

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部